CN107003301B - 用于诊断和预后肾损伤和肾衰竭的方法和组合物 - Google Patents

用于诊断和预后肾损伤和肾衰竭的方法和组合物 Download PDF

Info

Publication number
CN107003301B
CN107003301B CN201580068922.9A CN201580068922A CN107003301B CN 107003301 B CN107003301 B CN 107003301B CN 201580068922 A CN201580068922 A CN 201580068922A CN 107003301 B CN107003301 B CN 107003301B
Authority
CN
China
Prior art keywords
hours
subject
serum creatinine
scr
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580068922.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107003301A (zh
Inventor
J·安德贝里
P·麦克弗森
J·格雷
K·中村
J·P·坎普夫
T·关
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astute Medical Inc
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Priority to CN201910986041.5A priority Critical patent/CN110702921B/zh
Publication of CN107003301A publication Critical patent/CN107003301A/zh
Application granted granted Critical
Publication of CN107003301B publication Critical patent/CN107003301B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN201580068922.9A 2014-10-20 2015-10-20 用于诊断和预后肾损伤和肾衰竭的方法和组合物 Active CN107003301B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910986041.5A CN110702921B (zh) 2014-10-20 2015-10-20 用于诊断和预后肾损伤和肾衰竭的方法和组合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462066316P 2014-10-20 2014-10-20
US201462066313P 2014-10-20 2014-10-20
US201462066310P 2014-10-20 2014-10-20
US62/066,310 2014-10-20
US62/066,313 2014-10-20
US62/066,316 2014-10-20
PCT/US2015/056462 WO2016064877A2 (en) 2014-10-20 2015-10-20 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910986041.5A Division CN110702921B (zh) 2014-10-20 2015-10-20 用于诊断和预后肾损伤和肾衰竭的方法和组合物

Publications (2)

Publication Number Publication Date
CN107003301A CN107003301A (zh) 2017-08-01
CN107003301B true CN107003301B (zh) 2019-11-01

Family

ID=55761743

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580068922.9A Active CN107003301B (zh) 2014-10-20 2015-10-20 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN201910986041.5A Active CN110702921B (zh) 2014-10-20 2015-10-20 用于诊断和预后肾损伤和肾衰竭的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910986041.5A Active CN110702921B (zh) 2014-10-20 2015-10-20 用于诊断和预后肾损伤和肾衰竭的方法和组合物

Country Status (13)

Country Link
US (2) US11333671B2 (enExample)
EP (2) EP3968022A1 (enExample)
JP (4) JP6792553B2 (enExample)
KR (1) KR102431003B1 (enExample)
CN (2) CN107003301B (enExample)
AU (2) AU2015336069B2 (enExample)
BR (1) BR112017008218A2 (enExample)
CA (1) CA2965153C (enExample)
EA (1) EA201790696A1 (enExample)
ES (1) ES2907551T3 (enExample)
MX (1) MX388231B (enExample)
PT (1) PT3210018T (enExample)
WO (1) WO2016064877A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388231B (es) 2014-10-20 2025-03-19 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal.
EP4063853A1 (en) * 2017-01-12 2022-09-28 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement
US11346846B2 (en) 2017-02-06 2022-05-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3732196A4 (en) 2017-12-28 2022-01-05 Astute Medical, Inc. ANTIBODIES AND ASSAYS FOR CCL14
AU2019249070B2 (en) * 2018-04-02 2024-06-13 Potrero Medical, Inc. Systems, devices and methods for draining and analyzing bodily fluids and assessing health
US12114978B2 (en) 2018-04-02 2024-10-15 Potrero Medical, Inc. Systems, devices and methods for draining and analyzing bodily fluids and assessing health
US20220236285A1 (en) * 2019-05-24 2022-07-28 Astute Medical, Inc. Methods for evaluation and treatment of renal injury based on c-c motif chemokine ligand 14 measurement
US20230290457A1 (en) * 2020-03-23 2023-09-14 Biocogniv Inc. Artificial intelligence medical device
GB2596142B (en) * 2020-06-19 2023-11-29 Secr Defence Methods and associated uses, kits and systems for assessing sepsis
AU2021381364A1 (en) * 2020-11-18 2023-06-22 Astute Medical, Inc. Methods and compositions for treatment of renal injury and renal failure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646695A (zh) * 2002-02-12 2005-07-27 夸克生物技术公司 Axl受体在诊断和治疗肾病中的应用
WO2011017682A1 (en) * 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Devices for detecting renal disorders
WO2013096740A1 (en) * 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
ATE177841T1 (de) 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6811773B1 (en) * 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US20120064089A1 (en) * 2002-11-15 2012-03-15 Morehouse School Of Medicine Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
US7833732B2 (en) 2005-07-21 2010-11-16 The John Hopkins University Acute renal injury
EP1996013A4 (en) 2005-09-21 2010-03-10 Dask Technologies Llc METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES
US20110059537A1 (en) 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
AU2009223784A1 (en) 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
CN104020284B (zh) * 2008-10-21 2016-08-24 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
NZ599105A (en) * 2009-09-21 2014-08-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201290192A1 (ru) * 2009-11-07 2013-02-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
MX2012005210A (es) * 2009-11-07 2012-08-03 Astute Medical Inc Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US20120156701A1 (en) 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DK2666872T3 (en) * 2010-02-05 2016-07-25 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency
WO2011162821A1 (en) * 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN103080743B (zh) 2010-06-23 2015-07-22 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US20130203074A1 (en) 2010-06-23 2013-08-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9410968B2 (en) 2011-04-04 2016-08-09 Universiteit Gent Biomarkers for acute kidney injury
ES2721907T3 (es) * 2011-08-26 2019-08-06 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20160003850A1 (en) 2013-02-26 2016-01-07 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX388231B (es) 2014-10-20 2025-03-19 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646695A (zh) * 2002-02-12 2005-07-27 夸克生物技术公司 Axl受体在诊断和治疗肾病中的应用
US20090042826A1 (en) * 2002-02-12 2009-02-12 Quark Pharmaceuticals, Inc. Use of the AXL receptor for diagnosis and treatment of renal disease
WO2011017682A1 (en) * 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Devices for detecting renal disorders
WO2013096740A1 (en) * 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Biomarkers in chronic kidney disease:a review;RobertG.Fassett et al;《Kidney International》;20110622;第80卷;第806-821页 *
Gas6 and the Receptor Tyrosine Kinase Axl in Clear Cell Renal Cell Carcinoma;Anna Gustafsson et al;《PLoS ONE》;20091030;第4卷(第10期);第1-10页 *
HCC-1, a Novel Chemokine from Human Plasma;Peter Schulz-Knappe, et al;《J.Exp.Med.》;19960131;第183卷;第295-299页 *
Juan Antonio Moreno et al.Role of chemokines in proteinuric kidney disorders.《 Expert Reviews in Molecular Medicine》.2014,第16卷第1-22页. *
Tyro3 受体酪氨酸激酶亚家族的研究进展;蒋毅 等;《中国组织化学与细胞化学杂志》;20050831;第14卷(第4期);第466-469页 *

Also Published As

Publication number Publication date
BR112017008218A2 (pt) 2018-01-09
US12099067B2 (en) 2024-09-24
CA2965153C (en) 2023-10-24
EP3210018A2 (en) 2017-08-30
US20220236286A1 (en) 2022-07-28
CN110702921A (zh) 2020-01-17
WO2016064877A3 (en) 2016-09-09
JP6792553B2 (ja) 2020-11-25
AU2015336069A1 (en) 2017-05-25
EP3968022A1 (en) 2022-03-16
JP2017533427A (ja) 2017-11-09
JP7002623B2 (ja) 2022-02-10
ES2907551T3 (es) 2022-04-25
EP3210018A4 (en) 2018-06-20
JP2023052587A (ja) 2023-04-11
JP2022046669A (ja) 2022-03-23
US11333671B2 (en) 2022-05-17
CN110702921B (zh) 2024-02-06
PT3210018T (pt) 2021-10-04
EP3210018B1 (en) 2021-07-28
JP7217796B2 (ja) 2023-02-03
CA2965153A1 (en) 2016-04-28
EA201790696A1 (ru) 2017-10-31
AU2022201130A1 (en) 2022-03-17
MX2017005126A (es) 2017-09-15
WO2016064877A2 (en) 2016-04-28
CN107003301A (zh) 2017-08-01
JP2021039112A (ja) 2021-03-11
US20180209990A1 (en) 2018-07-26
KR102431003B1 (ko) 2022-08-09
AU2015336069B2 (en) 2021-11-25
AU2022201130B2 (en) 2024-06-27
KR20170084102A (ko) 2017-07-19
MX388231B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
CN107976547B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN103874923B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
JP7217796B2 (ja) 腎障害および腎不全の診断および予後のための方法および組成物
CN103238068B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102792161A (zh) 肾损伤和肾衰竭的诊断及预后的方法及组合物
HK1200218A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102725635B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN110431422A (zh) 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
HK1212770A1 (zh) 用於腎損傷和腎衰竭的診斷及預後的方法和組合物
HK1220764A1 (zh) 肾损伤和肾衰竭的诊断及预後
CN103858008B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102884205B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102576012B (zh) 用于肾损伤和肾衰竭的诊断及预后方法和组合物
CN107003325A (zh) 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN104379758A (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN104335045B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
HK1207155A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105209914B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
HK1232600A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1232600A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN107709993A (zh) 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
HK1236621A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1174367B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1212774B (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure
HK1203620B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1236621

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1236621

Country of ref document: HK